|
[1]TORRE LA, BRAY F, SIEGEL RL, et al.Global cancer statistics, 2012[J].CA Cancer J Clin, 2015, 65 (2) :87-108.
|
|
[2]EL-SERAG HB.Epidemiology of viral hepatitis and hepatocellular carcinoma[J].Gastroenterology, 2012, 142 (6) :1264-1273.
|
|
[3]EL-SERAG HB, KANWAL F.Epidemiology of hepatocellular carcinoma in the United States:where are we?where do we go?[J].Hepatology, 2014, 60 (5) :1767-1775.
|
|
[4]TREPO C, CHAN HL, LOK A.Hepatitis B virus infection[J].Lancet, 2014, 384 (9959) :2053-2063.
|
|
[5]HEYWARD WL, LANIER AP, MCMAHON BJ, et al.Early detection of primary hepatocellular carcinoma.Screening for primary hepatocellular carcinoma among persons infected with hepatitis B virus[J].JA-MA, 1985, 254 (21) :3052-3054.
|
|
[6]BRUIX J, SHERMAN M.Management of hepatocellular carcinoma:an update[J].Hepatology, 2011, 53 (3) :1020-1022.
|
|
[7]European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer.EASL-EORTC clinica practice guidelines:management of hepatocellular carcinoma[J].JHepatol, 2012, 56 (4) :908-943.
|
|
[8]ZHANG C, CHEN X, LIU H, et al.Alpha fetoprotein mediates HBx induced carcinogenesis in the hepatocyte cytoplasm[J].Int JCancer, 2015, 137 (8) :1818-1829.
|
|
[9]YAO MJ, ZHAO JM, LU FM.Alpha-fetoprotein still is a valuable diagnostic and prognosis predicting biomarker in hepatitis B virus infection-related hepatocellular carcinoma[J].Oncotarget, 2016, 7 (4) :3702-3708.
|
|
[10]YAMAMOTO K, IMAMURA H, MATSUYAMA Y, et al.AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC[J].J Gastroenterol, 2010, 45 (12) :1272-1282.
|
|
[11]NAKAGAWA T, MIYOSHI E, YAKUSHIJIN T, et al.Glycomic analysis of alpha-fetoprotein L3 in hepatoma cell lines and hepatocellular carcinoma patients[J].J Proteome Res, 2008, 7 (6) :2222-2233.
|
|
[12]JIA ZL, WANG L, LIU C, et al.Clinical significance of alpha-fetoprotein variant in diagnosis of liver cancer[J].China Cancer, 2010, 19 (10) :686-688. (in Chinese) ) 贾志凌, 王莉, 刘畅, 等.甲胎蛋白异质体对肝癌诊断的临床意义[J].中国肿瘤, 2010, 19 (10) :686-688.
|
|
[13]HU B, TIAN X, SUN J, et al.Evaluation of individual and combined applications of serum biomarkers for diagnosis of hepatocellular carcinoma:a meta-analysis[J].Int J Mol Sci, 2013, 14 (12) :23559-23580.
|
|
[14]YI X, YU S, BAO Y.Alpha-fetoprotein-L3 in hepatocellular carcinoma:a meta-analysis[J].Clin Chim Acta, 2013, 425:212-220.
|
|
[15]LIEBMAN HA, FURIE BC, TONG MJ, et al.Des-gammacarboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma[J].N Engl J Med, 1984, 310 (22) :1427-1431.
|
|
[16]KIM DY, PAIK YH, AHN SH, et al.PIVKA-II is a useful tumor marker for recurrent hepatocellular carcinoma after surgical resection[J].Oncology, 2007, 72 (Suppl 1) :52-57.
|
|
[17]JI J, WANG H, LI Y, et al.Diagnostic evaluation of des-gamma-carboxy prothrombin versus alpha-fetoprotein for hepatitis B virus-related hepatocellular carcinoma in China:a large-scale, multicentre study[J].PLo S One, 2016, 11 (4) :e153227.
|
|
[18]LI C, ZHANG Z, ZHANG P, et al.Diagnostic accuracy of desgamma-carboxy prothrombin versusα-fetoprotein for hepatocellular carcinoma:a systematic review[J].Hepatol Res, 2014, 44 (10) :e11-e25.
|
|
[19]MAO Y, YANG H, XU H, et al.Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma[J].Gut, 2010, 59 (12) :1687-1693.
|
|
[20]ZHU YW, YAO MJ, LV QJ, et al.Diagnostic evaluation of serum Golgi protein 73 (GP73) for cirrhosis among Chinese chronic hepatitis C patients[J].Hepatol Int, 2017, 11 (Suppl 1) :s1013-s1014.
|
|
[21]WANG L, YAO MJ, ZHAO JM, et al.Golgi protein 73:a valuable serum marker for the diagnosis of fibrosis and cirrhosis of non-alcoholic fatty liver disease[J].Hepatol Int, 2017, 11 (Suppl 1) :s60.
|
|
[22]YAO MJ, ZHAO JM, LU FM.Serum Golgi protein 73 is not a valuable diagnostic marker for hepatocellular carcinoma[J].Hepatol Int, 2017, 11 (Suppl 1) :s172-s173.
|
|
[23]YAO MJ, ZHAO JM, LU FM.Serum Golgi protein 73 is a valuable diagnostic biomarker in HBV infection-related significant fibrosis and early cirrhosis[J].Hepatol Int, 2017, 11 (Suppl 1) :s922-s923.
|
|
[24]WANG LJ, LI YM, YAO MJ, et al.Serum Golgi protein 73 is a valuable non-invasive marker for the diagnosis of fibrosis and cirrhosis in patients with autoimmune liver diseases[J].Hepatol Int, 2017, 11 (Suppl 1) :s924-s925.
|
|
[25]LI MY, YAO MJ, ZHAO JM, et al.Serum golgi protein 73 values to the early diagnosis of autoimmune liver diseases-related cirrhosis[J].Hepatol Int, 2017, 11 (Suppl 1) :s925.
|
|
[26]YAN Y, YAO MJ, ZHAO JM, et al.Diagnostic evaluation of serum golgi protein 73 (GP73) for alcoholic liver cirrhosis among Chinese patients[J].Hepatol Int, 2017, 11 (Suppl 1) :s201-s202.
|
DownLoad: